Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Youyi Fong, Yunda Huang, David Benkeser, Lindsay N. Carpp, Germán Áñez, Wayne Woo, Alice McGarry, Lisa M. Dunkle, Iksung Cho, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Julia Hütter, Maryam Keshtkar‐Jahromi, Tatiana Beresnev, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Julie A. Ake, Cynthia L. Gay, Karen L. Kotloff, Richard A. Koup, Rubén O. Donis, Peter B. Gilbert, Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team, United States Government (USG)/CoVPN Biostatistics TeamNature Communications 2023 · DOI · OpenAlex

Introduction

In the realm of clinical research, particularly concerning global health crises like the COVID-19 pandemic, the integrity and transparency of data analysis are fundamental. This article serves as a formal publisher correction for the study "Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial," originally published in Nature Communications in January 2023. The correction addresses a clerical omission regarding the trial's Statistical Analysis Plan (SAP).

The Importance of the Statistical Analysis Plan (SAP)

A Statistical Analysis Plan is a comprehensive document that outlines the technical details of the planned statistical analyses for a clinical trial. It is typically authored and finalized before the data are unblinded or analyzed. The SAP is vital for several reasons:

  • Transparency: It provides a clear roadmap of how the researchers intended to treat the data before results were known.
  • Prevention of Bias: By pre-specifying methods, it prevents "p-hacking" or the "cherry-picking" of results that might appear favorable after data collection.
  • Reproducibility: It allows independent researchers to audit the methodology and attempt to replicate the findings using the same statistical framework.

The Nature of the Correction

During the original publication process, a technical error occurred within the submission system (specifically the "ejp" pipeline). Consequently, while the study's findings on immune correlates—biomarkers such as antibody levels that indicate protection against COVID-19—were published, the accompanying SAP was inadvertently omitted from the supplementary materials.

This correction restores the SAP to the supplementary information. It ensures that the mathematical frameworks and statistical tests used to evaluate the Novavax (NVX-CoV2373) vaccine efficacy are fully accessible to the scientific community. The update ensures that all figures and tables from the original supplementary information are now correctly paired with the foundational analysis plan.

Impact on Original Findings

It is important to note that this correction is administrative in nature. The underlying data from the PREVENT-19 clinical trial and the conclusions drawn in the original paper remain unchanged. The restoration of the SAP serves to reinforce the original findings by providing the full context of the intended methodology, thereby upholding the standards of peer review and scientific rigor.

Conclusion

The publication of this correction highlights the ongoing commitment to transparency in high-stakes vaccine research. Even in top-tier journals, administrative errors can occur; however, the rectification of such errors is essential for maintaining the accountability necessary for public trust in clinical trial outcomes. The complete record for the PREVENT-19 immune correlates analysis is now available for full scientific audit.

Summary updated

BibTeX
@inproceedings{fong2023publisher,
  author = {Youyi Fong and Yunda Huang and David Benkeser and Lindsay N. Carpp and Germán Áñez and Wayne Woo and Alice McGarry and Lisa M. Dunkle and Iksung Cho and Christopher R. Houchens and Karen Martins and Lakshmi Jayashankar and Flora Castellino and Christos J. Petropoulos and Andrew Leith and Deanne Haugaard and Bill Webb and Yiwen Lu and Chenchen Yu and Bhavesh Borate and Lars W. P. van der Laan and Nima S. Hejazi and April K. Randhawa and Michele P. Andrasik and James G. Kublin and Julia Hütter and Maryam Keshtkar‐Jahromi and Tatiana Beresnev and Lawrence Corey and Kathleen M. Neuzil and Dean Follmann and Julie A. Ake and Cynthia L. Gay and Karen L. Kotloff and Richard A. Koup and Rubén O. Donis and Peter B. Gilbert and Immune Assays Team and Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team and United States Government (USG)/CoVPN Biostatistics Team},
  title = {{Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial}},
  booktitle = {Nature Communications},
  year = {2023},
  doi = {10.1038/s41467-023-37367-2},
}
Figure